MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by a ...

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Kati ...

MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September. Lake Street Big8 Best Ideas Growth Conference - NeuroPace management will host one-on-one meetings with investors at the Lake Street Big8 Best Ideas Growth Conference on Thursday, September 12th in New York. Cantor Global Healthc ...

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA. NeuroPace will also present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which ...

koto_feja In February, I was last picking up the pace in the case of NeuroPace, Inc. (NASDAQ:NPCE) after shares doubled since September 2023, aided by strong operating momentum. After shares tripled in a relatively short period of time, it was an opportune time to take some profits. By now, shares have lost half their value again, increasing the appeal, yet I find it too early to add to a current small speculative position here. An Epilepsy Play NeuroPace aims to improve the lives of epilepsy patients, by r ...

NeuroPace, Inc. (NPCE) reported a second-quarter 2024 loss of 26 cents per share compared with the year-ago quarter's reported loss of 36 cents. The figure was also narrower than the Zacks Consensus Estimate of a loss of 29 cents per share. Q2 Revenues Revenues totaled $19.3 million, up 16.9% year over year. The figure topped the Zacks Consensus Estimate by 2.9%. The revenue growth was driven by increased sales of the RNS System. Margins The gross profit in the reported quarter was $14.1 million, up 18.1% y ...

NeuroPace, Inc. (NASDAQ:NPCE) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Robert Marcus - JP Morgan Michael Polark - Wolfe Research Operator Good afternoon and welcome to NeuroP ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or other jurisdiction of inco ...

NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 Increased full-year 2024 revenue guidance to $76 million to $78 million Demonstrated continued operating discipline as evidenced by further decrease in cash burn Management scheduled to host a conference call today at 4:30 p.m. ET Mountain View, Calif. – August 13, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transform ...

NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Vik Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Michael Polark - Wolfe Research Drew Ranieri - Morgan Stanley Operator Good afternoon and welcome to NeuroPace's F ...